跳至主要内容
临床试验/CTRI/2021/05/033511
CTRI/2021/05/033511尚未招募未知

Comparative Efficacy of Aripiprazole and Olanzapine on Neurocognitive Profile of patients with Schizophrenia

Government Medical College and Hospital0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • . Patient or nominated representative willing for consent
  • 2. Patient in age group of 18-50years
  • 3. Patients diagnosed with schizophrenia according to DSM 5 criteria with total duration
  • of illness less than 5 years
  • 4. Patients who have never received aripiprazole and/or olanzapine in the past

排除标准

  • Patients with Treatment Resistant Schizophrenia (TRS)
  • 2. Patients with neurological disorders â?? head injury, tumours, movement disorders
  • (except antipsychotic induced), dementia, organic brain syndromes (eg. delirium,
  • amnesia), epilepsy.
  • 3. Patients who have received ECT in past 3 months
  • 4. Patients with co-morbid substance dependence (except nicotine and Caffeine)
  • 5. Patients who are lactating or pregnant
  • 6. Patients who received cognitive remediation in recent past.
  • 7. Patients diagnosed with any unstable medical (hypothyroidism, diabetes insipidus,
  • kidney disease, myasthenia gravis, chronic heart disease) or surgical disorders.
  • 8. Patients with subnormal intelligence.
  • 9. Actively Suicidal patients.

研究者

发起方
Government Medical College and Hospital

相似试验

To Compare the changes in Neurocognitive profile in... | 临床试验